Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C

Study achieves primary endpoint; tenapanor well-tolerated in treated patients Company to hold conference call at 8:30 a.m. ET today FREMONT, Calif., May 12, 2017 -- (Healthcare Sales & Marketing Network) -- Ardelyx, Inc. (NASDAQ: ARDX), a late-stage... Biopharmaceuticals, Gastroenterology Ardelyx, T3MPO-1 trial, IBS-C, tenapanor
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news